Company Overview and News


Add AGIO
to your dashboard

Headline News

Agios Posts New Data on Glioma Candidate from Dose Expansion

2017-11-20 zacks
Agios Pharmaceuticals, Inc. (AGIO - Free Report) announced new data from the dose expansion part of a phase I study, evaluating its IDH1 mutant inhibitor, ivosidenib (AG-120), as a single agent for treating low grade isocitrate dehydrogenase-1 mutant (IDH1m) glioma. Data was presented at the annual meeting of the Society for Neuro-Oncology (“SNO”) in San Francisco. (115-0)

7 ‘Strong Buy’ Stocks With 100% Wall Street Support | InvestorPlace

2017-11-17 investorplace
Which hot stocks are Wall Street analysts the most bullish on? The top stocks with no “hold” or “sell” ratings and a pure “strong buy” analyst consensus rating. Such strong buy stocks make for the most compelling investment opportunities — and I recommend keeping a close eye on them as we roll into 2018. (257-1)

Puma Biotechnology Faces Balance Sheet Anxiety

2017-11-10 seekingalpha
This loss will likely drive sell side analysts to push back expectations for break-even EBITDA to 2020 from 2019. (52-2)

36 Stocks For November 2017

2017-11-06 seekingalpha
Every month, we construct a theoretical long/short portfolio of stocks that demonstrates solid relative value with potential for ongoing cash flow growth and ROIC expansion. (703-1)

Agios (AGIO) Q3 Loss Narrower than Expected, Revenues Up Y/Y

2017-11-02 zacks
Agios Pharmaceuticals, Inc. (AGIO - Free Report) posted third-quarter 2017 loss of $1.59 per share, narrower than both the Zacks Consensus Estimate of a loss of $1.74 and the year-ago loss of $1.63. (100-0)

Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q3 2017 Results - Earnings Call Transcript

2017-11-01 seekingalpha
Good morning and welcome to Agios' Third Quarter 2017 Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session at the end. Please be advised that this call is being recorded at Agios' request. I would now like to turn the call over to Kendra Adams, Senior Director, Investor and Public Relations. (9-0)

Agios Pharmaceuticals, Inc. 2017 Q3 - Results - Earnings Call Slides

2017-11-01 seekingalpha
The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with their 2017 Q3 earnings call. (9-0)

Agios (AGIO) Q3 Loss Narrower than Expected, Sales Beat

2017-11-01 zacks
Agios Pharmaceuticals, Inc. (AGIO - Free Report) is a development-stage biopharmaceutical company focused on the development of treatments for cancer and rare genetic metabolic disorders. (20-0)

REIT Q3 Earnings: Key Predictions for ARE, AVB, UDR, VNO

2017-10-27 zacks
We will now tread into another busy week of the current reporting cycle and real estate investment trust (REIT) will buzz with activity on Monday itself. Among the factors that influenced the REIT space, a sluggish yet steady macroeconomic improvement is worth mentioning. This led to strong demand for a number of asset categories in third-quarter 2017. Though supply has been increasing, the pace has been modest in many of the asset categories. (67-0)

Agios Pharmaceuticals (AGIO) Q3 Earnings: What's in Store?

2017-10-27 zacks
Agios Pharmaceuticals, Inc. (AGIO - Free Report) is scheduled to report third-quarter results on Nov 1, before the opening bell. (69-0)

Will Cost Overruns Mar Southern Company's (SO) Q3 Earnings?

2017-10-27 zacks
Electric utility firm Southern Company (SO - Free Report) is set to release third-quarter 2017 results before the opening bell on Nov 1. (25-0)

What's in Store for Marathon Oil (MRO) This Earnings Season?

2017-10-27 zacks
Energy explorer Marathon Oil Corporation (MRO - Free Report) is set to release third-quarter 2017 results after the closing bell on Nov 1. (24-0)

What's in Store for Conatus (CNAT) This Earnings Season?

2017-10-27 zacks
Conatus Pharmaceuticals Inc. (CNAT - Free Report) is expected to report third-quarter 2017 results on Nov 1, after the market closes. (74-0)

Is Celgene (CELG) Poised for a Beat This Earnings Season?

2017-10-23 zacks
Celgene Corporation (CELG - Free Report) is scheduled to report third-quarter 2017 results on Oct 26, before the opening bell. (126-0)

CUSIP: 00847X104